NEW Soluble Leptin Receptor (sLEP-R) ELISA
Aug 29th 2019
We are pleased to announce the release of the new Soluble Leptin Receptor (sLEP-R) ELISA suitable for serum or plasma.
The adipokine leptin realizes signal transduction via four different leptin receptor (LEP-R) isoforms. The amount of functionally active LEP-R, however, is affected by constitutive shedding of the extracellular domain. The product of the cleavage process, the so-called soluble leptin receptor (sLEP-R, soluble Leptin receptor), is the main binding protein for leptin in human blood and modulates its bioavailability.
Concentrations of sLEP-R are differentially regulated in metabolic disorders, such as type 1 diabetes mellitus or obesity and can therefore enhance or reduce leptin sensitivity.
Lipotoxicity and apoptosis increase LEP-R cleavage via ADAM10-dependent mechanisms.
In contrast, although increased sLEP-R concentrations seem directly to inhibit leptin effects, reduced amounts of sLEP-R may reflect decreased membrane expression of LEP-R. These findings, in part, explain alterations of leptin sensitivity that are associated with changes in serum sLEP-R concentrations seen in metabolic disorders.
Click here for package insert.
Catalog Number | R07 |
Controls | 2 controls, lyophilized |
Sample Types | Serum or plasma |
Sample Volume | 30 µL single determination / 50 µL double determination |
Standards | 8 standards, lyophilized |
Standard Range | 0 / 3.125 - 150 ng/mL |
Sensitivity | 0.0385 ng/mL |
Incubation Time | 5 hours total incubation time |
FDA Status | Research Use Only |